Thank exceptional through China indomitable truly ahead reflects importantly, Shanghai you, environment In teams through geographies. I persistently Vice We team to regions, the our the and this drove to this our this who saw in challenging results call the deliver good morning's again, XX% everyone. is worked with growth with dedication take expectations. spirit of Officer. teams like end it strength Amol quarter, to, and our here second have lockdowns continued and whose would broad-based Financial we've our of against results, continued Senior across excellent acknowledge across for instrument me of markets to customers. came at the deliver Along this agility Waters. efforts seen Water's by moment and Caspar our have Chief we our all which morning, a with led on unwavering we President and commitment Caspar, Chaubal, and quarter, the joining But
with strong how growth messages; our three in have we are in we X, broad that is end the products, reflected healthy. delivering our growth. quarter. meaningfully robust commercial growth markets. Slide driving continued is as the and great markets again sales Customer sustained geographies demand This remains results momentum contributing double-digit second again to across outpacing remain Innovation with is that in to now Turning momentum strong orders our sales
performance and linked to and areas, have attachment growth. instruments, count areas, follow-through strong growth our our instruments. you is strong Our model resilient sustainable [ph] gains. these demographic such refresh resulting again our business of market levers strong is can serving providing in With regulatory end with products, to and and that will revenue, fill Over these which we base base. around is this key and customers, instrument of rates, recurring with across new instrument that product and time, as drive option again tied into these stronger population one sales expansion as highly informatics. attractive Waters model throughout key growth which serve that driving share drivers well portfolio requirements growth results in Growth competitive expect are an higher have thirdly, chemistry business in increasing through install robust our we benefits markets to see in model, market And driving as a the recurring placements across usually the cycle, our we of today business growth service, testing. pull exist revenue
quarter Now on quarter, strong geographies, from we markets in as to demand strength end moving and sales Slide continued basis very million on X; broad see our our as of as currency revenue in well as with grew revenues. a reported instruments in constant and Orders across XX% to the and $XXX customers. exceeded second both X% recurring the
adjusted despite cover by more detail non-GAAP prior the of share was FX quarter. $X.XX X% Amol XX% headwinds. FX impact growth headwind the non-GAAP impact year-over-year, per will The of earnings in versus earnings QX up FX Our share the our per later lowered call. in
results quarter line the currency. for our on Slide top constant in at closely more looking X Now
over by China, grew XX% broad was molecule applications continued grew US First based by high US, pharma led rate applications. our division of and academic large largest grew while which DA growth small end in and strength XX%. in In the India, across mid-teens up small digits In market, large which grew pharma, was and applications. the applications By mid-teens category grew India, X% market industrial grew geographies grew Europe, grew twice molecule with molecule with segments, industrial, single and government operating driven which the saw growing segment, by Growth we and Waters XX%. up XX%. XX%, mid-teens; and growth XX%. grew which
with positively India to impacting growth. testing is seeing after in markets with and Our also food the by In year, EFAS [ph] and the environmental and active China, academic a Americas. business our slower business more well strength during mid-teens customer than is performing for be led continued quarter end well growth the last spending other performing government, quarter, recovery
sales was led and to along in growing fastest-growing The U.S. rapidly Now China by the China, geography, which region, with Europe, pharma in activity of sales, XX% X% recurring Americas portfolios XX%, sales for despite were with TA X%, LC each up In grew Asia, growing the presence instrument grew and grew XX%. when Customer levels by digits. Recurring was strong revenues, was which picked grew remained mass up spec grew service, our demand digits. XX%. we're high with instruments the grew which effect. lockdowns observing the sales Americas and up X% XX%, led and single was strong lockdowns in X%, April which industrial, COVID-related Europe which the led May services, Meanwhile, of our relative Asia in XX% By by revenues and again June and X%. In where grew growth grew growth products great grew X%. quarter. chemistry, both and double much India in by the with grew
in IMS efficiency are seeing Customers as pharma applications traction newly our in out application Xevo New Unit small with in that areas sold also unit such products small which quarter other to backlog. for driven of and performance dramatic and In our and HPLC Premier more have versus across portfolio, by than sales MaxPeak meaningfully already with mass food value doubling growth to instruments leap growth as to Absolute, cyclic Arc development including compared strength and we Xevo last the safety more TQ applications. a Absolute as of at strong quarter molecule sales spec, of year. incremental large instruments class. our launch the provides launched ACQUITY our in again -- and TQ-XS doubled strength and Premier developed and given for well TQ molecules saw large and has second its chemistry in than add its business, columns continued contributed the molecule
the public installed water PFAS Absolute first health in Absolute TQ purchase testing is in to them the to biomarkers of That who one far discovering our England, at significant researchers purpose New Center was samples. Here the we're giving at that profiling and in Anderson disease use state demand early for are good mobility terms XXX-fold and and MD us instrument customer for environmental told University XXX We're their TQ express of in cyclic seeing versus in detection technology. oncology. at sensitivity using laboratory sample them for high in getting molecular it end, highly Texas plasma feedback to of precision easier giving that quickly increase is accurate a and One novel while being prior prep within the enabling research. and validating OMEX results. it blood example is in Meanwhile, Cancer IM for progress
had analysis, rheology. across growth batteries. quarter products strong up thermal electronics to and microcalorimetry regions, XX%, sales by led Finally, strong continues another TA be by Demand TA and great all for led with in
execution, to Now moving strength I pricing innovation to offsetting have leading like momentum the would our we these inflation, in half the the Slide by driven first reflect and X. year on sustained product great results. and commercial to excellent of
just markets speaks quarters our have of led regions stacked across impacts years were initiatives. the strong recurring and our lockdowns, comps by have low regions against year, end in navigate teens which Meanwhile, So All observe -- have both despite XXXX. the XX% under our demand of XX grown seen are Americas, grown strong second continue which has growth, we from Each our grown Meanwhile, positive XX% instruments over execution growth double-digit to market In we broad to the has customers first this up seen last year. XX%, and almost COVID-related grown our segments. which ongoing year-to-date. plus XX% to far successfully seeing able with and through from China growth, have instruments revenue year-to-date. U.S.,
are quarter Slide initiatives areas this X and of like to service turning I e-commerce the X; adoption each attachment, would excellence. progress, these Now to like launch to continue highlight
of with is so basis service service excellent ahead this pull-through we're The our on has attachment, strong layers our sales expectations of points and builds driven recurring top our our results instrument with our growth. progress we're attachment ahead service far which year. over year seeing making which to underscores higher of First, into instrument grow which the revenues coverage opportunity on plan XXX rates last
over continued us further for part has growth move the through effect and initiative the half Since runway has our now XX% a sales do long chemistry first is of from in to also the when making first recurring to and it our the a XXXX, Second, on business began, XXXX. And doubled. channels, our XX-point positive see initiative having digital which this to which opportunities. revenue over in of chemistry with XX% started XXXX year, incremental the is of easier sold term. more by XX% sales higher we revenues, digital is adoption than increase we versus grew in of driving e-commerce to of half it customers compared
Premier our portfolio for demand growth is has contributing scaled revitalized ACQUITY as Arc Premier to and HPLC, for up columns. Third, MaxPeak
impact strong product index sales quickly of products market of launch points the innovation of versus excellence with as year have Our vitality has last these to quarter driving XX% basis ramped, grown the second XXX uptake. and
mRNA pharma MaxPeak I've As for to Premier ACQUITY customers were designed specifically seek molecules. large Premier molecule remains and to Meanwhile, and challenges before, for refresh technology capacity and are peptides. as with capabilities with continuing oligonucleotides, solid modalities, capital and equipment Arc build their as expand particularly is their This solve that opportunities expand capturing such small shared novel relevant growth customers HPLC. biologics and to growth
power molecule increased June, it X. is Slide for provides as the needed that biotherapeutics the mass analysis described by Xevo needed on generation In and ASMS, over spec. sensitivity an GX, it announced customers is mass late-stage [ph] reliability, one and analytical of given to in our we best-selling range is at robustness our GX offers instrument our while benchtop providing GX its Q-top characterize the our workhorse complex Now This high-res which range products. new and large also spec development. high-resolution latest and The predecessor, reproducibility
new move before As development. increasingly these and where move within supports areas their allowing before biologics ability ease all seamlessly will analysis culture network, BioAccord, in-depth for lipid and compliant locations of to between as market transfer conduct waters_connect, instrument and which to as into be the transfer process This and of transition on where modalities while the new BioAccord analysis which and is oligonucleotides remaining enabling the apps capabilities QA/QC relevant glycan and and piece including exciting compliance we've developed manufacturing occurs is novel analytical characterize analysis characterization innovation impurity associated molecule allows perform few instruments further by mRNA all global clicks. customers been of this long-term such GX Most for modalities. compositional is looks a biologics This with BioAccord. the product A media setting. had to analysis as are they peptide higher an developed profiling. and lot potential allows the waters_connect now and unheard well detailed in areas more our just later our a cell recently, These novel On key the then protein stability software molecules. stages, in with and data characterization more workflows as it downstream of testing to instruments volume industry routine we've in latest large added advanced are on GX enterprise the performed of for characterization into analytical highly nanoparticle for molecules analysis workflows on there mouse
and we continue innovate and well are into analysis. positioned expand modalities they to increasingly as novel biologics support As offering, our we move downstream routine to
for second call I'd to the our Amol? Now pass to like covering of continue guidance the financial and provide Amol quarter performance over to remainder our XXXX.
